摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

β-cyclodextrin | 7585-39-9

中文名称
——
中文别名
——
英文名称
β-cyclodextrin
英文别名
5,10,15,20,25,30,35-Heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
β-cyclodextrin化学式
CAS
7585-39-9
化学式
C42H70O35
mdl
——
分子量
1135.0
InChiKey
WHGYBXFWUBPSRW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    290-300 °C (dec.) (lit.)
  • 比旋光度:
    [α]D25 +159~+165° (c=1, H2O) (After Drying)
  • 沸点:
    844.96°C (rough estimate)
  • 密度:
    1.2296 (rough estimate)
  • 溶解度:
    1M NaOH:50 mg/mL
  • LogP:
    -9.06
  • 物理描述:
    DryPowder, Liquid; Liquid
  • 旋光度:
    [α]D/25 + 160° to + 164° (1 % solution)

计算性质

  • 辛醇/水分配系数(LogP):
    -15
  • 重原子数:
    77
  • 可旋转键数:
    7
  • 环数:
    21.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    554
  • 氢给体数:
    21
  • 氢受体数:
    35

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间的使用总结:葛缕子(Carum carvi)种子含有多种挥发性油,其中最主要的是香旱芹醇和柠檬烯。葛缕子被认为是一种催乳剂,但在波斯传统医学中也被用来减少乳汁过量。建议母亲使用以减少母乳喂养婴儿的腹痛。没有科学有效的临床试验支持这些用途,尽管一项小型、古老的研究没有发现催乳效果。催乳剂不应替代影响乳汁产量的可修改因素的评估和咨询。两项研究发现,在接受化学实验的母亲乳汁中发现了少量d-香旱芹醇。美国食品药品监督管理局认为葛缕子“一般认为是安全的”。它通常耐受性良好,主要的副作用是胃肠道反应,如胃灼热、打嗝、腹胀和恶心。在两项研究中,哺乳期母亲服用了d-香旱芹醇。母亲或婴儿没有出现不良反应。 膳食补充剂不需要经过美国食品药品监督管理局的广泛市场前审批。制造商负责确保安全,但在上市前不需要证明膳食补充剂的安全性和有效性。膳食补充剂可能含有多种成分,标签上标注的成分或其含量与实际成分或含量之间往往存在差异。制造商可以与独立组织签订合同,以验证产品或其成分的质量,但这并不证明产品的安全或有效性。由于上述问题,对一种产品的临床测试结果可能不适用于其他产品。关于膳食补充剂的更详细信息可以在LactMed网站的其它地方找到。 ◉ 对母乳喂养婴儿的影响:一项研究比较了三组女性。一组20名哺乳期母亲每三天摄入一次30毫克d-香旱芹醇,连续28天(共10次),每次约在“通常”哺乳时间前2小时摄入,每次摄入量为75克鹰嘴豆泥。第二组20名哺乳期母亲遵循相同的饮食方案,但她们的鹰嘴豆泥不含d-香旱芹醇。第三组8名母亲接受了d-香旱芹醇风味的鹰嘴豆泥,但她们完全用配方奶喂养婴儿。在这28天结束后,两组母乳喂养的婴儿比配方奶喂养的婴儿更能接受d-香旱芹醇风味的土豆泥。作者解释这些结果意味着母乳喂养的婴儿比配方奶喂养的婴儿更能接受各种口味。 ◉ 对泌乳和母乳的影响:一组5名哺乳期母亲在前5天不服草药,接下来的10天每天3次服用15毫升10%的葛缕子种子浸液,然后从第15天到第20天再进行5天的对照期。在研究期间,他们的饮食和环境保持不变。每天测量乳汁量,在第5天、第10天、第15天和第20天测量乳汁脂肪百分比。没有发现对乳汁量或脂肪百分比的影响。由于缺乏随机化、盲法和对照,以及参与者数量较少,无法从这项研究中得出葛缕子催乳效果的任何有效结论。 一项随机试验将早产儿的母亲分配到每天两次服用所谓的草药催乳茶、每天两次服用果茶或什么都不服。催乳茶混合物(Natal, Hipp [土耳其])含有1%的荨麻,以及未指明剂量的甜、葛缕子、八角、茴香、山羊豆和柠檬草。所有母亲都接受了相同的哺乳建议,两组被告知茶会增加乳汁产量,但没有评估对研究茶剂的依从性。母亲使用吸奶器提取和测量她们的乳汁,并比较了第1天和第7天的产出。尽管催乳茶组的提取乳汁量增加更多,但7天后两组的母亲血清催乳素没有差异。各组之间婴儿体重增长没有差异,尽管作者指出除了泵出的乳汁外,所有婴儿都额外补充了营养。该研究没有采用盲法,随机化方法没有说明,没有进行意向治疗分析,一些数字结果内部不一致,因此研究质量较差。
◉ Summary of Use during Lactation:Caraway (Carum carvi) seeds contain numerous volatile oils, the most prominent being carvone and limonene. Caraway is a purported galactogogue, but it has also been used to decrease breastmilk oversupply in Persian traditional medicine. Maternal use has been advocated to reduce colic in the breastfed infant. No scientifically valid clinical trials support these uses, although one small, old study found no galactogogue effect. Galactogogues should never replace evaluation and counseling on modifiable factors that affect milk production. Two studies found small, but measurable amounts of d-carvone in the milk of mothers given the chemical experimentally. Caraway is "generally recognized as safe" by the U.S. Food and Drug Administration. It is usually well tolerated, with the primary side effects being gastrointestinal such as heartburn, eructation, flatulence, and nausea. In two studies nursing mothers were given d-carvone. No adverse effects were noted in mothers or infants. Dietary supplements do not require extensive pre-marketing approval from the U.S. Food and Drug Administration. Manufacturers are responsible to ensure the safety, but do not need to prove the safety and effectiveness of dietary supplements before they are marketed. Dietary supplements may contain multiple ingredients, and differences are often found between labeled and actual ingredients or their amounts. A manufacturer may contract with an independent organization to verify the quality of a product or its ingredients, but that does not certify the safety or effectiveness of a product. Because of the above issues, clinical testing results on one product may not be applicable to other products. More detailed information about dietary supplements is available elsewhere on the LactMed Web site. ◉ Effects in Breastfed Infants:A study compared 3 groups of women. One group of 20 nursing mothers consumed 30 mg of d-carvone in 75 grams of hummus every third day for 28 days (10 exposures) at about 2 hours before a "usual" nursing time. A second group of 20 nursing mothers followed the same regimen, but their hummus contained no d-carvone. A third group of 8 mother received the d-carvone flavored hummus, but were exclusively formula feeding their infants. After this 28-day period, both groups of breast-fed infants showed greater acceptance of d-carvone-flavored mashed potatoes than the formula-fed infants who preferred the unflavored potatoes. The authors interpreted these results to mean that breastfed infants are more receptive to a wide array of flavors than formula-fed infants. ◉ Effects on Lactation and Breastmilk:A group of 5 nursing mothers were given no herb for 5 days, 15 mL of a 10% infusion of caraway seeds 3 times daily for 10 days, followed by another 5-day control period from days 15 to 20. Their diet and environment were kept constant during the study period. Milk volume was measured daily and milk fat percentage was measured on days 5, 10, 15 and 20. No effect on milk volume or percentage of fat was seen. Because of the lack of randomization, blinding and controls, and small number of participants, no valid conclusion can be made from this study on the galactogogue effects of caraway. A randomized trial assigned mothers of preterm infants to receive either a purported herbal galactogogue tea twice daily, a fruit tea twice daily or nothing. The galactogogue tea mixture (Natal, Hipp [Turkey]) contained 1% stinging nettle as well as melissa, caraway, anise, fennel, goat's rue, and lemon grass in unspecified amounts. All mothers received similar breastfeeding advice from the same nurse and two groups were told that the tea would increase milk production, but compliance with the study teas was not assessed. Mother used breast pumps to extract and measure their milk and output on day 1 and day 7 of the study were compared. Although the increase in volume of extracted milk was greater in the galactogogue tea group, there was no difference in maternal serum prolactin between the groups at 7 days. No difference in infant weight gain was seen between groups, although the authors stated that additional supplementation was provided to all infants in addition to the pumped milk. The study was not blinded, the randomization method was not stated, intent-to-treat analysis was not performed, and some of the numerical results were internally inconsistent, so the quality of the study was poor.
来源:Drugs and Lactation Database (LactMed)
毒理性
  • 副作用
职业性肝毒素 - 第二性肝毒素:在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒病例。
Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
毒理性
  • 毒性数据
LC50 (大鼠) > 4,900 毫克/立方米/4小时
LC50 (rat) > 4,900 mg/m3/4hr
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

安全信息

  • TSCA:
    Yes
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    1,2
  • 海关编码:
    3505100000
  • 危险品运输编号:
    NONH for all modes of transport
  • 危险性防范说明:
    P261,P304+P340
  • 危险性描述:
    H332
  • 储存条件:
    +15°C至+30°C

SDS

SDS:ee9c6c098960b6db6b765cc195080415
查看
Name: Beta-Cyclodextrin Material Safety Data Sheet
Synonym: Cycloheptaamylose; Alpha-3-Schardinger Dextrin; C
CAS: 7585-39-9
Section 1 - Chemical Product MSDS Name:Beta-Cyclodextrin Material Safety Data Sheet
Synonym:Cycloheptaamylose; Alpha-3-Schardinger Dextrin; C

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
7585-39-9 Beta-Cyclodextrin hydrate ca.100% 231-493-2
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7585-39-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 310 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C42H70O35
Molecular Weight: 1135.00

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7585-39-9: GU2293000 LD50/LC50:
CAS# 7585-39-9: Oral, mouse: LD50 = >12500 mg/kg; Oral, rat: LD50 = 18800 mg/kg.
Carcinogenicity:
Beta-Cyclodextrin hydrate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 7585-39-9: 0
Canada
CAS# 7585-39-9 is listed on Canada's DSL List.
CAS# 7585-39-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7585-39-9 is listed on the TSCA inventory.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

β-环状糊精作为新型药用辅料主要用于增加药物的稳定性、防止药物化与分解,提高药物的溶解度和生物利用度,降低药物的毒副作用,并掩盖药物的异味和臭气。

在食品制造方面,主要用来消除异味、提高香料香精及色素的稳定性、增强乳化能力和防潮能力,从而提升食品品质。

β-环状糊精还广泛应用于中药制剂领域中,可增加药物的溶解度,提高药物的稳定性,使液体药物粉末化,防止挥发性成分挥发,降低药物的刺激性和毒性。

此外,它也用于分离有机化合物及有机合成、络合剂、酶活性研究、组织培养剂等。

生产方法 第一种生产方法

以马铃薯、玉米、小麦等加工的淀粉为原料,经过以下步骤可得环糊精

  1. 淀粉悬浮液在70-80℃下液化;
  2. 乙醇反应并加热失活后过滤;
  3. 浓缩干燥。
第二种生产方法

直链淀粉为原料,在高浓度的淀粉悬浮液中,于80~85℃、环糊精葡萄糖转位酶(CGT酶)的作用下液化成低黏度淀粉;再在65℃和pH值8.5条件下进一步转化为环糊精。反应物中约含α-CD3I.5%、β-CD13.4%、γ-CD7.8%和其他糊精47.3%,浓缩后β-CD由于溶解度小易于结晶析出,结晶含有99%的β-CD。

第三种生产方法

以土豆、玉米、小麦等加工的淀粉为原料,经一种碱性淀粉酶(CGT-ase)作用过滤、浓缩可得饴状产品,亦可再经喷雾干燥得粉状产品。

第四种生产方法

淀粉解后经过环糊精葡萄糖酶的作用得到β-环糊精。纯化过程是由β-环糊精与含有杂质化合物的溶剂分离后,将溶剂蒸汽汽提,然后作最后纯化。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    β-cyclodextrinsodium methylate三苯基膦 作用下, 以81%的产率得到5,10,15,20,25,30,35-Heptakis(iodomethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
    参考文献:
    名称:
    七咪唑基-β-环糊精与阴离子表面活性剂分子诱导聚集的比较研究
    摘要:
    摘要带有七个阳离子臂的β-环糊精衍生物及其单电荷类似物,即per-6-deoxy-6-(1-methylimidazol-3-ium-3-yl)-β-cyclodextrin(3)和mono-6合成并充分表征了-脱氧-6-(1-甲基咪唑-3-基-3-基)-β-环糊精(4)。通过UV-vis,NMR,Zeta电位,动态光散射(DLS)研究了它们对两种阴离子表面活性剂(十二烷基磺酸钠(SDS)和磺基琥珀酸二辛酯(Aerosol OT,AOT))的诱导聚集行为。透射电子显微镜。结果表明,基质3可以诱导阴离子表面活性剂的分子聚集,其浓度远低于其原始CAC,从而导致较大的直径,
    DOI:
    10.1016/j.cclet.2014.11.028
  • 作为试剂:
    描述:
    吲哚3-氯-DL-丙氨酸aluminum(III) sulfate吡哆醛β-cyclodextrin 作用下, 反应 0.5h, 生成 DL-色氨酸
    参考文献:
    名称:
    Mimics of tryptophan synthetase and of biochemical dehydroalanine formation
    摘要:
    DOI:
    10.1021/ja00299a064
点击查看最新优质反应信息

文献信息

  • [EN] COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN<br/>[FR] COMPOSITIONS COMPRENANT UNE SOURCE MÉTALLIQUE, UN DITHIOCARBAMATE ET UNE CYCLODEXTRINE
    申请人:DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
    公开号:WO2018069525A1
    公开(公告)日:2018-04-19
    The present invention provides a novel class of dithiocarbamate-metal complexes and their uses in medicine. Also provided by the invention are combinations and pharmaceutical compositions, comprising a dithiocarbamate (or thiuram disulphide) such as disulfiram and cyclodextrin, with a source of a heavy metal. Surprisingly, the inventors found a synergistic potentiation of the anti-tumor effect, when a dithiocarbamate/heavy metal mixture was combined with a cyclodextrin. The compounds and combination of the invention are particularly useful in the treatment of tumor diseases, and other disorders. Provided are the compounds, combination, pharmaceutical compositions and kits, as well as methods for the preparation of the combinations of the invention.
    本发明提供了一种新型的二氨基甲酸属络合物及其在医学中的用途。该发明还提供了一种组合物和药物组合物,包括二氨基甲酸盐(或二乙基)如二硫酸铜环糊精,以及一种重属的来源。令人惊讶的是,发明人发现当将二氨基甲酸盐/重属混合物与环糊精结合时,抗肿瘤效果呈现协同增强作用。本发明的化合物和组合物在肿瘤疾病和其他疾病的治疗中特别有用。提供了本发明的化合物、组合物、药物组合物和试剂盒,以及制备本发明组合物的方法。
  • CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
    申请人:Cole Roderic O.
    公开号:US20140357557A1
    公开(公告)日:2014-12-04
    Methods and compositions relating to CDP-JAK inhibitor conjugates are described herein.
    这里描述了与CDP-JAK抑制剂共轭物相关的方法和组合物。
  • Asymmetric aldol condensation of acetyl ferrocene with aromatic aldehydes via the formation of the β-cyclodextrin inclusion complexes
    作者:Li Yue-Ming、Yao Xiao-Jie、Feng Xiao、Wang Xue-Mei、Wang Ji-Tao
    DOI:10.1016/0022-328x(95)05816-8
    日期:1996.3
    By the formation of β-cyclodextrin (β-CD) inclusion complex, the aldol condensation of the acetyl ferrocene (FcCOCH3) with aromatic aldehyde was investigated. The study reveals that the definite asymmetry-inducing ability of β-CD gives optical yields of the products in the range 6.0–30.4%. Also, alkali metal halides at a lower reaction temperature, can also give different results on the stereoselectivity
    通过形成β-环糊精(β-CD)包合物,研究了乙酰基二茂铁(FcCOCH 3)与芳香醛的醛醇缩合反应。研究表明,β-CD的确定的不对称诱导能力使产物的光学收率在6.0–30.4%的范围内。同样,在较低反应温度下的碱属卤化物也可以在反应体系的立体选择性上给出不同的结果。当在固态条件下进行实验时,获得了提高的光学产率。
  • Preparation of (η5-cyclopentadienyl) and (η5-methylcyclopentadienyl) Fe(CO)2 Me cyclodextrin inclusion compounds and their subsequent ligand substitution reactions. Attempts at cyclodextrin mediated enantioselective ligand substitution
    作者:Paren P Patel、Mark E Welker
    DOI:10.1016/s0022-328x(97)00181-2
    日期:1997.11
    Two iron complexes, (η5-Cyclopentadienyl)Fe(CO)2Me and (η5-Methylcyclopentadienyl)Fe(CO)2Me, were prepared followed by their α, β, and γ cyclodextrin inclusion compounds. The included iron complexes participate in phosphine induced ligand substitution reactions under both thermal and photochemical conditions with no CO insertion/alkyl migration products observed in either case.
    两个络合物,(η 5 -环戊二烯基)(CO)2我和(η 5 -Methylcyclopentadienyl)的Fe(CO)2 Me中,得到制备后,通过α,β,和γ环糊精包合的化合物。包括的络合物在热和光化学条件下均参与膦诱导的配体取代反应,在两种情况下均未观察到CO插入/烷基迁移产物。
  • [EN] ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME<br/>[FR] ANALOGUES DE L'ACIDE ARACHIDONIQUE ET PROCÉDÉS POUR UN TRAITEMENT ANALGÉSIQUE L'UTILISANT
    申请人:CYTOMETIX INC
    公开号:WO2011066414A1
    公开(公告)日:2011-06-03
    The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of r manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. The analogs are additionally useful as antipyretic compositions and in related fever reducing treatments.
    本发明提供了花生四烯酸AA)类似物以及含有这些类似物作为活性剂的组合物,用于镇痛治疗。提供了制造创新化合物的各种方法,并描述了包括注射剂和口服剂量在内的药物配方。这些类似物还可用作退热组合物以及相关的降热治疗。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台